Description
BYL719 (alpelisib) is a selective PI3K alpha inhibitor that has been evaluated in colorectal cancer treatment combinations. In CRC clinical trials, it is used specifically for BRAF-mutated metastatic colorectal cancer in combination with other targeted agents like cetuximab and LGX818 (encorafenib). The drug has also been tested with capecitabine and radiation therapy for rectal cancer treatment.
Mechanism of Action
BYL719 selectively inhibits the PI3K alpha isoform, which is part of the PI3K/AKT/mTOR signaling pathway that regulates cell growth, proliferation, and survival. By blocking PI3K alpha activity, the drug disrupts downstream AKT signaling, leading to reduced tumor cell proliferation and enhanced apoptosis in cancer cells with PI3K pathway alterations.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Piqray |
| Category | Other Medications |
 Status | Off-label |
| Administration | Oral |
| Year Approved | 2019 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.